文献速递临床试验与 GCP

头孢曲松对比青霉素G治疗神经梅毒:多中心随机对照试验研究方案

Ceftriaxone compared with penicillin G for the treatment of neurosyphilis: study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2022-10-01

本研究为多中心随机对照试验,计划纳入290例新诊断神经梅毒患者,按1:1随机分配至水剂结晶青霉素G(ACPG)组或头孢曲松组,按中国国家指南标准方案治疗并随访12个月。主要结局包括脑脊液白细胞计数、血清学疗效和临床疗效,旨在评估头孢曲松治疗神经梅毒是否非劣效于ACPG。

要点

  • 多中心随机对照试验,计划纳入290例新诊断神经梅毒患者,1:1随机分组。
  • 两组分别接受ACPG或头孢曲松标准方案,随访12个月,在第3、6、9、12个月评估。
  • 主要结局为脑脊液白细胞计数、血清学疗效和临床疗效;次要结局包括脑脊液蛋白浓度、MMSE评分、影像学结果、复发和康复时间。

核心结论

  • 该试验旨在提供临床数据以确定头孢曲松治疗神经梅毒是否非劣效于ACPG,并为治疗指南的改进提供证据。

研究设计与样本

  • 多中心随机对照临床试验,计划纳入290例新诊断神经梅毒患者,按1:1随机分配至ACPG组或头孢曲松组。
  • 两组按中国国家指南的标准方案治疗,随访12个月,在基线及第3、6、9、12个月评估所有临床参数。
  • 主要结局包括脑脊液白细胞计数、血清学疗效和临床疗效;次要结局包括脑脊液蛋白浓度、MMSE评分、影像学结果、复发和神经梅毒康复时间。
  • 试验期间监测并记录不良事件。

关键数值与推荐

  • 计划纳入290例新诊断神经梅毒患者,按1:1随机分配至ACPG组或头孢曲松组。
  • 两组按中国国家指南的标准方案治疗,随访12个月,评估时间点为基线及第3、6、9、12个月。
  • 主要结局为脑脊液白细胞计数、血清学疗效和临床疗效。
  • 次要结局为脑脊液蛋白浓度、MMSE评分、影像学结果、复发和神经梅毒康复时间。
  • 试验注册号ChiCTR2100047164,2021年6月9日注册,2021年11月23日更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurosyphilis may cause irreversible neurological sequelae. First-line treatment consists of penicillin G, with ceftriaxone being an alternative treatment in patients allergic to penicillin. The lack of clinical data comparing the efficacy of these two drugs indicated the need for comparative clinical trials to improve national treatment guidelines in China. METHODS/DESIGN: In this multicenter randomized controlled clinical trial, 290 patients newly diagnosed with neurosyphilis will be randomized 1:1 to treatment with aqueous crystalline penicillin G (ACPG) or ceftriaxone. Patients will be treated with standard regimens of ACPG or ceftriaxone according to Chinese National Guidelines and will be followed up for 12 months. All clinical parameters will be assessed at baseline and at follow-up 3, 6, 9, and 12 months later. The primary outcomes will include cerebrospinal fluid (CSF) white blood cell (WBC) count, serological efficacy, and clinical efficacy. The secondary outcomes will include CSF protein concentrations, Mini-Mental State Examination (MMSE) scores, imaging results, recurrence, and time to recovery from neurosyphilis. Adverse events will be monitored and recorded during the trial. DISCUSSION: This trial will provide clinical data to determine whether ceftriaxone is non inferior to ACPG in treating neurosyphilis and will provide evidence for the improvement of treatment guidelines. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100047164. Registered on 9 June 2021 and updated on 23 November 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Du FZ, Wu MZ, Zhang X, et al. Ceftriaxone compared with penicillin G for the treatment of neurosyphilis: study protocol for a multicenter randomized controlled trial. Trials. 2022. PMID: 36183101. doi:10.1186/s13063-022-06769-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。